title: Preclinical approaches in chronic myeloid leukemia: from cells to systems.
abstract: Advances in the design of targeted therapies for the treatment of chronic myeloid leukemia (CML) have transformed the prognosis for patients diagnosed with this disease. However, leukemic stem cell persistence, drug intolerance, drug resistance, and advanced-phase disease represent unmet clinical needs demanding the attention of CML investigators worldwide. The availability of appropriate preclinical models is essential to efficiently translate findings from the bench to the clinic. Here we review the current approaches taken to preclinical work in the CML field, including examples of commonly used in vivo models and recent successes from systems biology-based methodologies.
authors.affiliation: Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, UK.
authors.forename: Cassie J
authors.initials: CJ
authors.lastname: Clarke
authors.affiliation: Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, UK. Electronic address: Tessa.Holyoake@glasgow.ac.uk.
authors.forename: Tessa L
authors.initials: TL
authors.lastname: Holyoake
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D002461:Cell Line, Transformed; D017690:Cell Transplantation; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D014161:Transduction, Genetic; D019076:Transgenes; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays